Total Payments
$3,690
2024 Payments
$172.27
Companies
38
Transactions
242
Medicare Patients
8,848
Medicare Billing
$1.5M
Payment Breakdown by Category
Food & Beverage$3,555 (96.3%)
Education$134.84 (3.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,555 | 226 | 96.3% |
| Education | $134.84 | 16 | 3.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $697.77 | 49 | $0 (2024) |
| PFIZER INC. | $397.19 | 38 | $0 (2019) |
| Amgen Inc. | $300.13 | 18 | $0 (2019) |
| Genentech USA, Inc. | $246.60 | 15 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $244.30 | 17 | $0 (2023) |
| Lilly USA, LLC | $140.29 | 9 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $129.40 | 7 | $0 (2021) |
| Astellas Pharma US Inc | $111.87 | 7 | $0 (2019) |
| Celgene Corporation | $107.90 | 4 | $0 (2024) |
| Exelixis Inc. | $107.37 | 6 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $172.27 | 7 | Celgene Corporation ($87.00) |
| 2023 | $39.36 | 2 | ABBVIE INC. ($23.72) |
| 2022 | $55.28 | 3 | E.R. Squibb & Sons, L.L.C. ($43.31) |
| 2021 | $61.03 | 4 | Boehringer Ingelheim Pharmaceuticals, Inc. ($25.17) |
| 2019 | $436.36 | 30 | Novartis Pharmaceuticals Corporation ($76.03) |
| 2018 | $1,493 | 101 | Novartis Pharmaceuticals Corporation ($375.97) |
| 2017 | $1,433 | 95 | Novartis Pharmaceuticals Corporation ($215.01) |
All Payment Transactions
242 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $26.09 | General |
| Category: Hematology | ||||||
| 11/07/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $18.49 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $27.57 | General |
| Category: Hematology | ||||||
| 09/26/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $19.62 | General |
| Category: ONCOLOGY | ||||||
| 09/05/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: ONCOLOGY | ||||||
| 07/31/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $33.34 | General |
| Category: Hematology | ||||||
| 05/07/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $30.76 | General |
| Category: Immunology | ||||||
| 05/30/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $23.72 | General |
| Category: ONCOLOGY | ||||||
| 03/01/2023 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $15.64 | General |
| Category: Cardiovascular | ||||||
| 11/07/2022 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $23.96 | General |
| Category: Cardiovascular | ||||||
| 09/26/2022 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $19.35 | General |
| Category: Cardiovascular | ||||||
| 02/01/2022 | Acrotech Biopharma LLC | BELEODAQ (Drug) | Education | In-kind items and services | $11.97 | General |
| Category: ONCOLOGY | ||||||
| 11/10/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug), COSELA | Food and Beverage | In-kind items and services | $25.17 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 02/18/2021 | Acrotech Biopharma LLC | BELEODAQ (Drug) | Education | In-kind items and services | $11.97 | General |
| Category: ONCOLOGY | ||||||
| 01/28/2021 | Acrotech Biopharma LLC | BELEODAQ (Drug) | Education | In-kind items and services | $11.97 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2019 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Food and Beverage | Cash or cash equivalent | $14.69 | General |
| Category: Interventional Oncology | ||||||
| 05/06/2019 | Clovis Oncology, Inc. | Rubraca (Drug) | Education | In-kind items and services | $2.55 | General |
| Category: Oncology | ||||||
| 03/28/2019 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: HEMATOLOGY | ||||||
| 03/27/2019 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $11.60 | General |
| Category: Oncology | ||||||
| 03/27/2019 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $11.27 | General |
| Category: Oncology | ||||||
| 03/25/2019 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $13.74 | General |
| Category: Oncology | ||||||
| 03/24/2019 | Astellas Pharma US Inc | XOSPATA (Drug) | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: ONCOLOGY | ||||||
| 03/19/2019 | Novartis Pharmaceuticals Corporation | SANDOSTATIN (Drug) | Food and Beverage | In-kind items and services | $21.11 | General |
| Category: ONCOLOGY | ||||||
| 03/05/2019 | GENZYME CORPORATION | LIBTAYO (Drug) | Food and Beverage | In-kind items and services | $23.13 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 40 | 2,230 | 33,019 | $1.6M | $290,249 |
| 2022 | 43 | 2,190 | 35,210 | $2.4M | $415,938 |
| 2021 | 40 | 2,198 | 26,194 | $2.3M | $443,069 |
| 2020 | 35 | 2,230 | 33,405 | $1.9M | $357,751 |
Total Patients
8,848
Total Services
127,828
Medicare Billing
$1.5M
Procedure Codes
158
All Medicare Procedures & Services
158 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 29 | 54 | $259,308 | $62,750 | 24.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 222 | 674 | $248,032 | $62,232 | 25.1% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 13 | 11,040 | $220,800 | $25,646 | 11.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 43 | 143 | $101,101 | $14,496 | 14.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 44 | 92 | $45,632 | $12,258 | 26.9% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 23 | 596 | $107,280 | $11,087 | 10.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 231 | 1,261 | $25,220 | $10,566 | 41.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 41 | 160 | $39,520 | $9,882 | 25.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 226 | 953 | $60,992 | $9,828 | 16.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 224 | 1,112 | $40,032 | $8,432 | 21.1% |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | Office | 2023 | 14 | 22 | $60,764 | $6,263 | 10.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 47 | 47 | $26,555 | $5,722 | 21.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 37 | 41 | $28,454 | $5,553 | 19.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 33 | 99 | $30,987 | $4,861 | 15.7% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 115 | 363 | $21,780 | $4,802 | 22.0% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 30 | 53 | $34,821 | $4,726 | 13.6% |
| 85055 | Reticulated (young) platelet measurement | Office | 2023 | 35 | 127 | $18,161 | $4,449 | 24.5% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 190 | 754 | $23,374 | $4,447 | 19.0% |
| 83550 | Iron binding capacity | Office | 2023 | 115 | 364 | $12,740 | $3,087 | 24.2% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 14 | 14 | $14,938 | $2,450 | 16.4% |
| 83540 | Iron level | Office | 2023 | 115 | 364 | $9,828 | $2,284 | 23.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 32 | 165 | $15,840 | $1,778 | 11.2% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 15 | 10,500 | $21,000 | $1,705 | 8.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 32 | 128 | $13,824 | $1,493 | 10.8% |
| 88184 | Flow cytometry technique for dna or cell analysis, first marker | Office | 2023 | 23 | 28 | $8,344 | $1,432 | 17.2% |
About Dr. Anwar Khurshid, MD
Dr. Anwar Khurshid, MD is a Hematology & Oncology healthcare provider based in Arlington, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/15/2005. The National Provider Identifier (NPI) number assigned to this provider is 1922000488.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anwar Khurshid, MD has received a total of $3,690 in payments from pharmaceutical and medical device companies, with $172.27 received in 2024. These payments were reported across 242 transactions from 38 companies. The most common payment nature is "Food and Beverage" ($3,555).
As a Medicare-enrolled provider, Khurshid has provided services to 8,848 Medicare beneficiaries, totaling 127,828 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 158 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Hematology & Oncology
- Location Arlington, TX
- Active Since 08/15/2005
- Last Updated 10/05/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1922000488
Products in Payments
- AFINITOR (Drug) $275.85
- BOSULIF (Drug) $174.90
- TASIGNA (Drug) $161.35
- Kyprolis (Biological) $138.01
- GILOTRIF (Drug) $129.40
- OPDIVO (Biological) $118.97
- Neulasta (Biological) $115.76
- JADENU (Drug) $107.56
- Cabometyx (Drug) $107.37
- IBRANCE (Drug) $103.75
- SUTENT (Drug) $91.64
- REBLOZYL (Biological) $87.00
- DARZALEX (Biological) $81.47
- Bavencio (Biological) $80.90
- CYRAMZA (Drug) $78.33
- Avastin (Biological) $72.87
- TECENTRIQ (Biological) $72.63
- Rubraca (Drug) $59.16
- CAMZYOS (Drug) $58.95
- XTANDI (Drug) $58.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Arlington
Neelima Denduluri, M.d, M.D
Hematology & Oncology — Payments: $95,053
Hematology & Oncology $95,053
Keeran Sampat, Md, MD
Hematology & Oncology — Payments: $22,287
Hematology & Oncology $22,287
Revathi Angitapalli, M.d, M.D
Hematology & Oncology — Payments: $20,808
Hematology & Oncology $20,808
John Adams, Do, DO
Hematology & Oncology — Payments: $16,414
Hematology & Oncology $16,414
Karel Dicke, Md Phd, MD PHD
Hematology & Oncology — Payments: $3,885
Hematology & Oncology $3,885
Isabelle Le, M.d, M.D
Hematology & Oncology — Payments: $3,686
Hematology & Oncology $3,686